Moleculin Operating Income vs Operating Expenses Analysis

MBRX
 Stock
  

USD 1.64  0.01  0.61%   

Moleculin Biotech financial indicator trend analysis is infinitely more than just investigating Moleculin Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moleculin Biotech is a good investment. Please check the relationship between Moleculin Biotech Operating Income and its Operating Expenses accounts. Additionally, see Stocks Correlation.

Operating Income vs Operating Expenses

Operating Income vs Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moleculin Biotech Operating Income account and Operating Expenses. At this time, the significance of the direction appears to have pay attention.
The correlation between Moleculin Biotech's Operating Income and Operating Expenses is -0.99. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Operating Expenses in the same time period over historical financial statements of Moleculin Biotech CS, assuming nothing else is changed. The correlation between historical values of Moleculin Biotech's Operating Income and Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Moleculin Biotech CS are associated (or correlated) with its Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Expenses has no effect on the direction of Operating Income i.e., Moleculin Biotech's Operating Income and Operating Expenses go up and down completely randomly.

Correlation Coefficient

-0.99
Relationship DirectionNegative 
Relationship StrengthSignificant

Operating Income

Operating Income is the amount of profit realized from Moleculin Biotech operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Moleculin Biotech CS is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Operating income is a measure of financial performance before the deduction of Interest Expense; Income Tax Expense and other Non-Operating items. It is calculated as [GP] minus Operating Expenses.

Operating Expenses

Operating expenses represents the total expenditure on [SGnA]; [RnD] and other operating expense items; it excludes [CoR].
Most indicators from Moleculin Biotech fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Additionally, see Stocks Correlation.Moleculin Biotech Issuance Purchase of Equity Shares is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Issuance Purchase of Equity Shares of 74.75 Million in 2021. Enterprise Value over EBIT is likely to rise to 1.08 in 2022, whereas Selling General and Administrative Expense is likely to drop slightly above 6.9 M in 2022.

Moleculin Biotech fundamental ratios Correlations

0.340.940.980.350.98-0.44-0.44-0.420.96-1.00.130.51-0.110.260.37-1.0
0.340.60.490.750.47-0.76-0.86-0.740.55-0.340.680.820.490.640.83-0.34
0.940.60.990.590.98-0.67-0.71-0.651.0-0.940.360.70.10.360.61-0.94
0.980.490.990.481.0-0.57-0.59-0.550.99-0.980.30.630.050.340.53-0.98
0.350.750.590.480.47-0.99-0.86-1.00.57-0.350.360.560.190.060.64-0.35
0.980.470.981.00.47-0.56-0.58-0.540.99-0.980.270.620.020.320.51-0.98
-0.44-0.76-0.67-0.57-0.99-0.560.91.0-0.650.44-0.38-0.61-0.2-0.09-0.670.44
-0.44-0.86-0.71-0.59-0.86-0.580.90.87-0.680.45-0.5-0.77-0.28-0.3-0.720.45
-0.42-0.74-0.65-0.55-1.0-0.541.00.87-0.630.42-0.35-0.57-0.18-0.05-0.640.42
0.960.551.00.990.570.99-0.65-0.68-0.63-0.960.270.650.010.30.53-0.96
-1.0-0.34-0.94-0.98-0.35-0.980.440.450.42-0.96-0.13-0.510.11-0.26-0.371.0
0.130.680.360.30.360.27-0.38-0.5-0.350.27-0.130.710.940.730.91-0.13
0.510.820.70.630.560.62-0.61-0.77-0.570.65-0.510.710.440.740.87-0.51
-0.110.490.10.050.190.02-0.2-0.28-0.180.010.110.940.440.580.750.11
0.260.640.360.340.060.32-0.09-0.3-0.050.3-0.260.730.740.580.66-0.26
0.370.830.610.530.640.51-0.67-0.72-0.640.53-0.370.910.870.750.66-0.37
-1.0-0.34-0.94-0.98-0.35-0.980.440.450.42-0.961.0-0.13-0.510.11-0.26-0.37
Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech fundamental ratios Accounts

201720182019202020212022 (projected)
Accounts Payable810 K1.25 M2.15 M1.13 M1.36 M1.2 M
Total Assets19.48 M19.59 M25.23 M29.03 M84.09 M90.73 M
Current Assets8.3 M7.97 M13.48 M17.2 M72.5 M78.22 M
Assets Non Current11.18 M11.61 M11.75 M11.83 M11.59 M11.84 M
Cash and Equivalents7.71 M7.13 M10.73 M15.17 M70.9 M76.5 M
Cash and Equivalents USD7.71 M7.13 M10.73 M15.17 M70.9 M76.5 M
Total Debt450 K296 K276 K159 K63 K64.66 K
Total Debt USD450 K296 K276 K159 K63 K64.66 K
Shareholders Equity17.12 M14.27 M15.57 M17.76 M78.99 M85.23 M
Shareholders Equity USD17.12 M14.27 M15.57 M17.76 M78.99 M85.23 M
Total Liabilities2.37 M5.31 M9.66 M11.27 M5.1 M5.52 M
Current Liabilities2.21 M3.88 M3.57 M2.92 M3.62 M3.35 M
Liabilities Non Current150 K1.44 M6.09 M8.35 M1.48 M1.51 M
Trade and Non Trade Payables810 K1.25 M2.15 M1.13 M1.36 M1.33 M
Property Plant and Equipment Net33 K463 K603 K685 K445 K422.33 K
Accumulated Retained Earnings Deficit(14.48 M)(26.36 M)(39.56 M)(56.92 M)(72.81 M)(74.73 M)

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moleculin Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pair Correlation Now

   

Pair Correlation

Compare performance and examine fundamental relationship between any two equity instruments
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
48 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.